Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Stark

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Clinical and Vaccine Immunology : CVI|September 8, 2012
Development of an inhalational Bacillus anthracis exposure therapeutic model in cynomolgus macaquesLisa N Henning, Jason E Comer, Gregory V Stark, et al.
Science Translational Medicine|September 14, 2012
Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challengeMichael P Fay, Dean A Follmann, Freyja Lynn, et al.
American Heart Journal|September 1, 1989
Planar positron imaging of rubidium-82 for myocardial infarction: a comparison with thallium-201 and regional wall motionK A Williams, J W Ryan, L Resnekov, et al.
Clinical and Vaccine Immunology : CVI|February 13, 2015
Efficacy and immunogenicity of single-dose AdVAV intranasal anthrax vaccine compared to anthrax vaccine absorbed in an aerosolized spore rabbit challenge modelVyjayanthi Krishnan, Bo H Andersen, Christine Shoemaker, et al.
Plos One|March 9, 2013
Clinical profiles associated with influenza disease in the ferret modelGregory V Stark, James P Long, Diana I Ortiz, et al.
Virology|March 11, 2014
Protection of ferrets from pulmonary injury due to H1N1 2009 influenza virus infection: immunopathology tractable by sphingosine-1-phosphate 1 receptor agonist therapyJohn R Teijaro, Kevin B Walsh, James P Long, et al.
Vaccine|August 5, 2017
Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidateVladimir Savransky, Jeffry D Shearer, Melicia R Gainey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Phase II trial of chemotherapy alone for primary CNS and intraocular lymphomaV Sandor, V Stark-Vancs, D Pearson, et al.
Vaccine|May 8, 2016
Evaluation of early immune response-survival relationship in cynomolgus macaques after Anthrax Vaccine Adsorbed vaccination and Bacillus anthracis spore challengeG S Sivko, G V Stark, K P Tordoff, et al.
Antimicrobial Agents and Chemotherapy|July 20, 2016
Efficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease SeverityBrent J Yamamoto, Annette M Shadiack, Sarah Carpenter, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Clinical and Vaccine Immunology : CVI|September 8, 2012
Development of an inhalational Bacillus anthracis exposure therapeutic model in cynomolgus macaquesLisa N Henning, Jason E Comer, Gregory V Stark, et al.
Science Translational Medicine|September 14, 2012
Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challengeMichael P Fay, Dean A Follmann, Freyja Lynn, et al.
American Heart Journal|September 1, 1989
Planar positron imaging of rubidium-82 for myocardial infarction: a comparison with thallium-201 and regional wall motionK A Williams, J W Ryan, L Resnekov, et al.
Clinical and Vaccine Immunology : CVI|February 13, 2015
Efficacy and immunogenicity of single-dose AdVAV intranasal anthrax vaccine compared to anthrax vaccine absorbed in an aerosolized spore rabbit challenge modelVyjayanthi Krishnan, Bo H Andersen, Christine Shoemaker, et al.
Plos One|March 9, 2013
Clinical profiles associated with influenza disease in the ferret modelGregory V Stark, James P Long, Diana I Ortiz, et al.
Virology|March 11, 2014
Protection of ferrets from pulmonary injury due to H1N1 2009 influenza virus infection: immunopathology tractable by sphingosine-1-phosphate 1 receptor agonist therapyJohn R Teijaro, Kevin B Walsh, James P Long, et al.
Vaccine|August 5, 2017
Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidateVladimir Savransky, Jeffry D Shearer, Melicia R Gainey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Phase II trial of chemotherapy alone for primary CNS and intraocular lymphomaV Sandor, V Stark-Vancs, D Pearson, et al.
Vaccine|May 8, 2016
Evaluation of early immune response-survival relationship in cynomolgus macaques after Anthrax Vaccine Adsorbed vaccination and Bacillus anthracis spore challengeG S Sivko, G V Stark, K P Tordoff, et al.
Antimicrobial Agents and Chemotherapy|July 20, 2016
Efficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease SeverityBrent J Yamamoto, Annette M Shadiack, Sarah Carpenter, et al.
Pageof 4